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Abstract
Pancreatic ductal adenocarcinoma (PDA) is the third leading cause of cancer related deaths in the 
U.S., while colorectal cancer (CRC) is the third most common cancer. The RNA binding protein 
HuR (ELAVL1), supports a pro-oncogenic network in gastrointestinal (GI) cancer cells through 
enhanced HuR expression. Using a publically available database, HuR expression levels were 
determined to be increased in primary PDA and CRC tumor cohorts as compared to normal 
pancreas and colon tissues, respectively. CRISPR/Cas9 technology was successfully used to delete 
the HuR gene in both PDA (MIA PaCa-2 and Hs 766T) and CRC (HCT116) cell lines. HuR 
deficiency has a mild phenotype, in vitro, as HuR-deficient MIA PaCa-2 (MIA.HuR-KO(−/−)) cells 
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had increased apoptosis when compared to isogenic wild-type (MIA.HuR-WT(+/+)) cells. Using 
this isogenic system, mRNAs were identified that specifically bound to HuR and were required for 
transforming a 2D culture into 3D (i.e., organoids). Importantly, HuR-deficient MIA PaCa-2 and 
Hs 766T cells were unable to engraft tumors in vivo compared to control HuR-proficient cells, 
demonstrating a unique xenograft lethal phenotype. While not as a dramatic phenotype, CRISPR 
knockout HuR HCT116 colon cancer cells (HCT.HuR-KO(−/−)) showed significantly reduced in 
vivo tumor growth compared to controls (HCT.HuR-WT(+/+)). Finally, HuR deletion affects KRAS 
activity and controls a subset of pro-oncogenic genes.
Implications—The work reported here supports the notion that targeting HuR is a promising 
therapeutic strategy to treat GI malignancies.
Keywords
HuR; CRISPR; Cas9; Pancreatic ductal adenocarcinoma; Colorectal cancer
Introduction
Pancreatic ductal adenocarcinoma (PDA), with an overall 5-year survival rate of roughly 7 
percent, is one of the deadliest solid tumors (1,2). Colorectal cancer (CRC) is the third most 
common cancer in the United States and the fourth most common cause of death worldwide 
(3). Both CRC and PDA tumorigenesis are associated with numerous sequential genetic 
changes (4). However, methods to target common mutations (KRAS, p16/DSKN2A, TP53) 
in PDA and CRC have been particularly challenging and shown limited therapeutic value 
(5,6). Genetic mutations and copy number changes are critical regulatory mechanisms 
promoting the initiation and progression of tumorigenesis. Beyond driving mutations, it is 
becoming clearer that post-transcriptional gene regulatory mechanisms play an important 
role in controlling the available transcriptome (7). Post-transcriptional gene regulation 
characteristically involves trans-acting microRNAs (miRNAs) and RNA-binding proteins 
(RBPs) that are potent regulators controlling the abundance of specific pro-oncogenic 
proteins (8,9).
Hu proteins are a family of trans-acting RBPs that recognize and bind to cis-acting AU-rich 
RNA elements (AREs) within the mRNA 3′ untranslated regions (3′ UTRs) (10). The 
RNA-binding protein HuR (ELAVL1) is expressed ubiquitously and is extensively involved 
in mRNA stability and translation. HuR targets, which include proto-oncogenes, cytokines, 
growth and invasion factors, implicate an important role of HuR in cancer development (11). 
HuR is abundant in both PDA and CRC specimens compared to normal adjacent tissue with 
cytoplasmic subcellular localization associated with increased tumor stage (12,13). As tumor 
cells are under stress in the tumor microenvironment (14) (e.g., nutrient deprivation and 
hypoxia) (15,16), HuR translocates from the nucleus, binds to pro-oncogenic mRNA 
transcripts (e.g. WEE1, PIM1, COX-2, VEGF), promoting cancer cell survival and 
tumorigenesis (14,17,18).
To further depict the role of HuR in GI cancer biology, we genetically deleted HuR in PDA 
and CRC cells by using clustered, regularly interspaced, short palindromic repeat (CRISPR)/
Cas9 technology. The system efficiently targets a specific genomic sequence and then 
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creates disruptive double strand breaks (DSB). The DSB is repaired via non-homologous 
end joining and thus insertions/deletions (INDELs) are randomly placed at the sites of repair 
(19). These INDELs can lead to deleterious frameshift mutations and ultimately premature 
stop codons to effectively disrupt the targeted gene on one (+/−) or both (−/−) alleles, and 
thus allowing an efficient way to generate an isogenic cell culture model in which to study 
the importance of HuR in GI cancer cells.
Materials and Methods
Evaluation of HuR mRNA in Pancreas Clinical Specimens
Previously reported microarray expression (20) data were downloaded from GEO (accession 
number: GSE71729). This dataset contains 46 normal pancreatic tissue samples, 145 
primary pancreatic adenocarcinomas, 42 normal colon and 286 primary colon 
adenocarcinomas. The relative expression levels for HuR was extracted from the 
downloaded matrix and used for comparisons between the three groups of samples.
Cell Culture, Transfections and Treatments
Cell culture conditions—MIA PaCa-2, Hs 766T and HCT116 cells were purchased from 
ATCC. Cells were cultured in DMEM supplemented with 10% FBS (Gibco/Invitrogen), 1% 
L-glutamine (Gibco/Invitrogen), and 1% penicillin-streptomycin (Invitrogen) at 37°C in 5% 
humidified CO2 incubators.
Transfections—MIA PaCa-2 and Hs 766T cells were seeded in 6-well plate at the density 
of 500,000 cells per well for 24 h. Cells transfected with approximately 5 μg of CRISPR 
control and HuR knockout plasmids using Lipofectamine 2000 (Gibco/Invitrogen) as 
previously described (14). Cells were harvested after 48 h of transfection and GFP positive 
cells were single sorted into 96-well plates using FACS Calibur flow cytometer (BD 
Biosciences, East Rutherford, NJ).
MIA.HuR-KO(−/−) cells were seeded in 6-well plate at the density of 500,000 cells per well 
and cells were transfected with HuR overexpression plasmid as previously described (21).
Treatments—Cells were treated with the IC50 values of the DNA damaging agent MMC 
(mitomycin C; Sigma, St. Louis, MO), gemcitabine (Eli Lilly) and oxaliplatin (Sigma) for 
24 h as previously described (14) by adding directly into the culture medium.
Note: All experiments using PDA CRISPR transfected cells were performed on cells 
passage between 10 – 25.
Plasmid Design
CRISPR knockout in MIA PaCa-2 and Hs 766T PDA cell lines—Three different 
guide RNAs of HuR fused with CRISPR-cas9 and GFP protein were designed and 
purchased from Sigma (St. Louis, MO; Fig. S1A and Supplementary Table S1). Guide RNA 
1 was located on exon 2 (sense), guide RNA 2 was also located on exon 2 (antisense) and 
guide RNA 3 was located on exon 3 (sense) (Supplementary Table S1). The CRISPR 
Universal Negative Control plasmid was purchased from Sigma (Cat. No. CRISPR06-1EA). 
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Plasmids were purified using Qiagen’s plasmid mini-purification kit following 
manufacture’s protocol (Qiagen, Hilden, Germany).
Note: In the figures, the MIA.HuR-WT(+/+) clone is ‘MIA.HuR’, MIA.HuR-KO(+/+) clone is 
‘Clone.4’, MIA.HuR-KO(−/−).1 clone is ‘Clone.11’, MIA.HuR-KO(−/−).2 clone is ‘Clone.14’ 
and MIA.HuR-KO(−/−) + HOE is ‘Clone.11 stably transfected with an HuR overexpression 
plasmid’.
CRISPR knockout in HCT116 colon cancer cell line—CRISPR/Cas9-mediated 
knockout of ELAVL1 in the human colon cancer cell line HCT116 (ATCC; Manassas, VA) 
was accomplished using HuR CRISPR/Cas9 KO plasmid (sc-400141; Santa Cruz 
Biotechnology), followed by homology-directed repair (HDR) insertion of a puromycin 
resistance gene/red fluorescent protein (RFP) cassette (sc-400141-HDR; Santa Cruz 
Biotechnology) into the double strand break according to the vendor’s protocol. Transfected 
cells were selected in normal growth medium containing 0.5 μg/mL puromycin 
(ThermoFisher Scientific) for 2–3 weeks. Individual clones were isolated using cloning 
cylinders, and HuR knockout clones screened by western blotting for HuR and genotyped by 
PCR to verify exon insertion of the Puro/RFP cassette. For stable cell maintenance, the 
puromycin concentration was reduced to 0.2 μg/mL.
Sequencing Analysis
Sanger sequencing was performed using sequencing primers listed in Table S2 on genomic 
DNA of the clones. The Sequencher software (Gene Codes Corporation, Ann Arbor, MI) 
was used to analyze the chromatogram and identify mutation sites. Sequence changes were 
classified according to the HGVS nomenclature recommendation and based on the NCBI 
reference sequence: NM_001419.2. Clone sequencing and expression data are provided in 
Supplementary table S4 and Fig. S1B and S1C. For simplicity, the clones employed in our 
experiments will be referred to as MIA.HuR-KO(−/−).1 (Clone.11, created with Guide RNA 
3), MIA.HuR-KO(−/−).2 (Clone.14, created with Guide RNA 3), MIA.HuR-KO(+/+) (Clone.
4, created with Guide RNA 1) and HsT.HuR-KO(−/−) (created with Guide RNA 3). These 
clones correlate with NM_001419[c.211delCG];[c.211delCG], 
NM_001419[c.204delGTGACCGCGA];[c.206delGACCGCGAAGGATGCAG], NM_001419 Wild Type 
and 
NM_00141
9[c.211_212insATGATAGTCCATTTTAAAACATAATTTTAAAACTGCAAACTAC] ;[c.211_212insATGATAGTCCATTTTAAAACATAATTTTAAAACTGCAAACTAC] 
mutation sites, respectively.
Whole Cell Extracts and SDS-PAGE/Western Blotting
Whole cell lysates were isolated using RIPA lysis buffer (Invitrogen) by incubating the cell 
pellets on ice for 10 minutes followed by centrifugation at 13,000 *g for 15 minutes at 4°C 
as previously described (14). Samples were then mixed 4:1 with 5X Laemmli buffer and 
boiled for 5 minutes. Proteins were measured with Pierce BCA kit (ThermoFisher) and 
approximately 50 μg was separated using a 12% Bis-Tris polyacrylamide gel and transferred 
to PVDF membrane (Invitrogen), blocked in 1:1 Licor Odyssey blocking buffer and 
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incubated overnight at 4°C with α-Tubulin (Santa Cruz; #sc-5286) and HuR (Santa Cruz; 
#sc-5261) antibodies. Protein complexes were then visualized with Licor Odyssey.
Immunofluorescence
Approximately 50,000 cells were plated on coverslips per well in 24-well plate. After 24 h, 
cells were treated with MMC, gemcitabine and oxaliplatin for 24 h. Cells were then washed 
2 times with 1X PBS, fixed with 4% paraformaldehyde for 10 minutes at room temperature, 
permeabilized with 0.25% Triton-X for 30 minutes, blocked with 5% goat serum for 1 h, and 
incubated overnight with HuR antibody, as previously described (14). DAPI was used to 
stain cell nuclei and coverslips were mounted with DAPI ProLong Gold Antifade 
(Invitrogen). Slides were visualized with a Zeiss LSM-510 Confocal Laser Microscope. All 
images were taken at 40X magnification with oil. Images were cropped using AIM browser.
Flow Cytometry Analysis
Cleaved caspase 3—Cells were seeded at 300,000 cells per well in 6-well plates for 24 
h. Apoptosis was measured by incubating the cells for 30 min with CellEvent™ Caspase-3/7 
Green Flow Cytometry Assay Kit (ThermoFisher Scientific), according to the 
manufacturer’s instructions, and analyzed using a FACS Calibur flow cytometer (BD 
Biosciences, East Rutherford, NJ). Calculated relative mean fluorescence intensity (MFI) 
was produced using FlowJo software (Tree Star, Inc., Ashland, OR).
Cell cycle—Cells were seeded at 500,000 cells per well in 6-well plates for 24 hours. Cells 
were pulse chased with BrdU (Amersham, Piscataway, NJ, USA) by adding directly to 
actively growing cells for 1 h as previously described (14) and analyzed on FACS Calibur 
flow cytometer. Graphs were generated on Excel (Microsoft).
Soft Agar Assay
A bottom layer of 0.75% agar was prepared in complete medium in 60 mm tissue culture 
dishes. A top layer of 0.36% agar supplemented with 10,000 cells/mL was added as 
previously described _ENREF_10(14). Pictures were taken using Floid Cell Imaging Station 
(Life Technologies) and colonies were counted using ImageJ (http://imagej.nih.gov/ij/).
Organoid Cultures
Cell lines were obtained from 2D culture (standard cell culture) and washed with cold 
organoid basic media. Cells are then spun at 1,200 rpm for 5 minutes and washed again. The 
pellet was suspended in matrigel and 50 μl of cell-matrigel mixture is added to each well of 
a pre-warmed 24 well plate. The plate was then placed in a standard tissue culture incubator 
until the matrigel solidified. 500 μl of pre-warmed complete organoid feeding media is then 
added to each well. The plates are placed in a tissue culture incubator and inspected on a 
daily basis as described in Boj et al and Baker et al (22,23). For all organoid cultures and 
studies, we validated HuR knockout for the CRISPR lines via qRT-PCR analysis (data not 
shown).
Image Analysis performed using Paint Shop Pro (Version 7.04, Corel Corporation, Ottawa 
ON, Canada) and R (Version 3.3.2, the R Foundation for statistical computing). Microscopic 
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images of identical magnification were digitally acquired at three time points (1280×960 
Pixels). Images were centered and cropped to 800×800 pixels. Organoid objects maps of the 
images were created using gray scale value thresholding and also visually assessed and 
corrected for merging and segmentation errors. The produced maps were assessed for size 
and number of objects per map using the EBImage: Image processing and analysis toolbox 
for R (http://rdrr.io/bioc/EBImage/). Objects with surface area smaller than 10 pixels were 
excluded from the analysis. Cell line organoid sizes were assessed for normality of 
distribution with the Kolmogorov-Smirnov test (24). Area size was compared using Mann-
Whitney test for non-parametric distributions and t-test for normal distributions(25). P 
values < 0.05 were considered as statistically significant.
Serum Starvation Assay
MIA.HuR-WT(+/+) and MIA.HuR-KO(−/−) cells growing in log phase in normal growth 
medium (RPMI 1640 + 10% FBS) were serum starved (0.1% FBS) for 16 h or 72 h. Cells 
were homogenized in lysis buffer (25 mM HEPES pH 7.5, 150 mM NaCl, 1% NP-40, 0.25% 
sodium deoxycholate, 10% glycerol, 10 mM MgCl2, 1× phosphatase and protease inhibitors 
(HALT, Thermo) and protein concentration was quantified by BCA assay (Pierce). A Ras-
GTP pulldown was performed according to previously established protocols (26,27). 
Western blot analysis was performed on the pulldown and straight protein lysate samples 
blotting for K-Ras and K-Ras-GTP (Calbiochem; #OP24), AKT (Cell Signaling; #4691), 
pAKT (Cell Signaling; #4060), MEK (Cell Signaling; #8727), pMEK (Cell Signaling; 
#9154) and Vinculin (Sigma; #V9131). Protein bands were visualized by Luminata ECL 
reagents (Millipore) on x-ray film or a FluorChem M (Protein Simple) imager. Protein bands 
were analyzed by densitometry, normalized for protein load against vinculin and relative to 
MIA.HuR-WT(+/+) signals.
MTT Assay
Cells were seeded at 5,000 cells/well in 96-well tissue culture plates. Cell growth was 
assayed using the MTT-based cell growth determination kit (Sigma-Aldrich) as previously 
described (28). Cell growth was calculated as relative absorbance (A570) normalized to cells 
after 1 day of growth. Data are represented as average of 3 independent experiments ± SEM.
Short-term Drug Sensitivity Assay
Cells were seeded at 1,000 cells/well in 96-well tissue culture plates in triplicates. Cells 
were treated 24 h later and exposed to only one dose. After 7-day of treatment, cells were 
washed, lysed, stained with PicoGreen (Invitrogen) and fluorescence intensity was read as 
previously described (29). Graph was generated using GraphPad (San Diego, CA). Data are 
represented as average of 3 independent experiments ± SEM.
RNP-IP and qPCR
Cells were plated at 50% confluency in 100 mm dishes. Cells were either left untreated or 
treated with 1 μM oxaliplatin for 24 h. Immunoprecipitation was performed using either 
anti-HuR or IgG control antibodies as previously described (14). Total RNA was isolated 
and WEE1, IDH1 and PARP1 mRNA binding was validated by RT-qPCR.
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In Vivo Experiment
MIA PaCa-2 and Hs 766T xenografts—The experiments involving mice received the 
approval of the Thomas Jefferson University Institutional Animal Care regulations and Use 
Committee (IACUC). Six week-old, female, athymic nude mice were purchased from 
Harlan Laboratories and 5 × 106 cells were injected subcutaneously in the left and right 
flanks, respectively (5 mice per group). Cells were prepared in 100 μL solution comprised of 
70% DPBS and 30% Matrigel. Tumor volumes and body weight were measured three times 
per week using a caliper, and tumor volumes were calculated using the formula Volume = 
Length × Width2/2. Upon termination of the experiment, mice were euthanized using carbon 
dioxide inhalation followed by cervical dislocation, and tumors were harvested.
HCT116 Xenografts—Athymic nude (Nu/Nu) mice were purchased from Jackson 
Laboratories and maintained under sterile conditions in cage micro-isolators according to 
approved IACUC guidelines. Parental HCT116 and HuR knockout clones 1 and 2 (2 × 106 
cells) used between passages 14 – 23 were resuspended in PBS containing 50% Matrigel 
(Corning) and injected into the dorsal subcutaneous tissue. Tumor growth was assayed as 
described (28,30).
Results
HuR mRNA is more abundant in primary GI tumors compared to normal tissue
We have previously demonstrated that HuR is upregulated in CRC cells (13). To determine 
HuR expression levels in pancreatic samples, we analyzed previously reported microarray 
data (20) of HuR mRNA levels in normal pancreatic tissues (n=46) and primary tumors 
(n=145) as well as in colon normal tissues (n=42) and primary tumors (n=286). We detected 
that HuR mRNA levels is enhanced slightly in both pancreatic (p<0.005) and colon 
(p<0.0005) primary tumors compared to normal tissues (Fig. 1A).
Successful generation of HuR knockout PDA cells using the CRISPR-Cas9 system
We transfected the PDA cell line MIA PaCa-2 cells, known to harbor common genetic 
lesions found in most PDAs (K-RAS, p53 and p16) (31), with three different guide RNAs 
designed to target exon 2 and 3 of human HuR (ELAVL1; Supplementary Table S1). A 
plasmid containing Cas9 protein fused with GFP and guide RNA expressed from a single 
vector was transfected to MIA PaCa-2 cells (Fig. S1A). As a control, a non-specific guide 
RNA in this vector was also transfected. Forty-eight hours post-transfection, cells were 
single sorted with FACS into 96-well plates. The mutation was confirmed by Sanger 
sequencing in expanded single cell colonies (Supplementary Table S2, S3, S4 and Fig. 1B). 
Only guide RNA 3 targeting the exon 3 of HuR resulted in producing 5 stable clones (Fig. 
1C, 1D; Supplementary Figs. S1B, S1C; Supplementary Tables S3 and S4). HuR mRNA 
levels were analyzed by qPCR (Fig. 1C and Supplementary Fig. S1B) and protein expression 
was detected by immunoblotting (Fig. 1D and Supplementary Fig. S1C), to demonstrate 
HuR gene expression correlated to the genotype. Both MIA.HuR-WT(+/+) (wild-type 
parental CRISPR control transfected cells showing homozygous wild type genotype) and 
MIA.HuR-KO(+/+) (HuR-CRISPR transfected cells showing homozygous wild type 
genotype; Supplementary Tables S3 and S4) clones displayed similar levels of HuR nucleo-
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cytoplasmic expression upon mitomycin C, gemcitabine and oxaliplatin stressors by 
immunofluorescence (Fig. 1E), indicating functional HuR translocation to the cytoplasm 
from the nucleus upon specific stress (14). The MIA.HuR-KO(−/−) (HuR-CRISPR 
transfected cells showing homozygous knockout/mutant genotype; Supplementary Tables S3 
and S4) cells showed no sign of HuR expression (Fig. 1E). We also created a CRISPR HuR 
knockout in another PDA cell line Hs 766T using guide RNA 3. The mutation in HuR was 
again confirmed by Sanger sequencing (Supplementary Fig. S1D and Supplementary Table 
S4) and functional inactivation of HuR was confirmed by immunoblot analysis 
(Supplementary Fig. S1E). These data demonstrate that the HuR gene was successfully 
knocked out using CRISPR-Cas9 system in multiple PDA cell lines.
HuR-deficient PDA cells have a mild phenotype in vitro
To determine the effect of HuR deletion has on the cancer phenotype, HuR knockout clone 
MIA.HuR-KO(−/−).1 along with controls, MIA.HuR-WT(+/+) and MIA.HuR-KO(+/+) were 
analyzed for in vitro growth viability with a trypan blue exclusion assay. Results 
demonstrated that MIA.HuR-KO(−/−).1 induced higher amounts of cell death compared to 
controls (Fig. 2A). In addition, cleaved caspase 3 activity, a marker of cell death, was 
measured with FACS and similar results were obtained (Fig. 2B–C), indicating HuR’s role 
in inhibiting apoptotic cell death. Taken together, these data demonstrate that the complete 
loss of HuR induces more cell death consistent with our previous work (32).
We have performed drug sensitivity assay (short-term cell survival) using a 
chemotherapeutic drug mitomycin C (MMC) and under glucose deprivation and observed 
that MIA.HuR-KO(−/−) cells are sensitive compared to controls (Supplementary Fig. S2A 
and B). To determine the long-term cell survival and anchorage independence growth, soft 
agar assays were performed. Results showed that loss of HuR (in the MIA.HuR-KO(−/−).1 
model) resulted in approximately 5-fold decrease in colony formation compared to controls 
(Fig. 2D and E). Lastly, the effects of HuR on cell cycle were analyzed by pulse-labeling the 
cells with bromodeoxyuridine (BrdU). Shown in Fig. 2F, MIA.HuR-KO(−/−).1 cells are 
primarily arrested in S phase with reduced number of cells in the G2/M phase, indicating 
that cells were cycling through mitosis and most likely prematurely dying.
In an effort to study a malignant characteristic of the HuR-deficient cells and how they 
would establish under the stressful transition from moving into a 3D culture, we evaluated 
the ability of each cell line’s capacity to transform into organoids (22). After 7–10 days of 
plating, MIA.HuR-KO(+/+) cells formed spheroids easily in 3D cultures within in a passage, 
while MIA.HuR-KO(−/−).2 cells only formed single cell sheets and were unable to form 
substantial spheroids even after 4 weeks of plating (Supplementary Figs. S2C and S2D). 
Image analysis of the spheroid structures in each group revealed the MIA.HuR-KO(+/+) 
spheroids to be significantly larger than the MIA.HuR-KO(−/−).2 spheroids (5–10 fold 
increase in cross-section area, P<0.01, Supplementary Fig. S2D). Furthermore, during the 
course of two weeks the MIA.HuR-KO(+/+) continued to grow and doubled in size (P<0.01) 
compared to the MIA.HuR-KO(−/−).2 spheroids. Similarly, when HsT.HuR-WT(+/+) and 
HsT.HuR-KO(−/−) cells were plated in 3D cultures the HsT.HuR-WT(+/+) demonstrated more 
robust spheroid formation and growth than the HsT.HuR-KO(−/−) cells (data not shown). 
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These data suggest that HuR is critical for initiation of growth in a stressful transition to 3D 
and also viability in a more relevant in vitro, 3D culture (22).
Using isogenic MIA.HuR-WT(+/+) and MIA.HuR-KO(−/−) PDA cells to identify HuR targets
It was previously published that HuR translocates to the cytoplasm upon specific stress 
where it binds to its mRNA targets and stabilizes their transcript and/or increases the protein 
translation (33). We and others have demonstrated that Ribonucleotide immunoprecipitation 
(RNP-IPs) assays (34) are a reliable and efficient way to capture HuR-bound mRNA targets 
(14,17,32,33,35). To evaluate binding of HuR to target mRNAs, two MIA.HuR-KO(−/−) 
(MIA.HuR-KO(−/−).1 and MIA.HuR-KO(−/−).2) cell lines along with controls MIA.HuR-
WT(+/+) and MIA.HuR-KO(+/+) cells were treated with oxaliplatin (1 μM) for 24 hours to 
induce cytoplasmic translocation (Fig. 3A). Cytoplasmic lysates were subjected to HuR 
immunoprecipitation (Fig. 3B), followed by analysis of HuR targets IDH1 and WEE1 by 
qPCR. Shown in Fig. 3C, PDA cells deficient in HuR showed background levels of IDH1 
and WEE1 mRNA, whereas control cells showed increased binding of HuR to these targets 
upon oxaliplatin stress. PARP1, a non-target of HuR, showed no significant binding in 
knockout as well as in controls samples (Fig. 3C).
HuR is required for PDA tumor growth
Since we were able to obtain viable HuR-deficient cancer cell lines (see Fig. 1B–E) and the 
in vitro phenotype was not dramatic for the MIA PaCa-2 line (Fig. 2), we evaluated if loss of 
HuR would disrupt cancer cell viability and growth in vivo. To test the effect of HuR 
knockout on in vivo PDA tumor growth, we first performed two individual experiments 
utilizing nude mice subcutaneously injected in their hind flanks with equal numbers of 
MIA.HuR-WT(+/+), MIA.HuR-KO(+/+) and two of different MIA.HuR-KO(−/−) cells 
(MIA.HuR-KO(−/−).1 and MIA.HuR-KO(−/−).2). Tumor volumes and body weight were 
measured three times per week and harvested after 48 days of tumor growth, Shown in Fig. 
4A, tumors derived from the MIA.HuR-WT(+/+) and MIA.HuR-KO(+/+) groups were 1976.7 
mm3 and 1305.8 mm3, respectively. The mean tumor volumes generated from MIA.HuR-
KO(+/+) cells were not significantly smaller than those from MIA.HuR-WT(+/+) cells 
(P<0.716; Fig. 4B and P<0.589; Supplementary Fig. S3A). However, this is in sharp contrast 
to both MIA.HuR-KO(−/−).1 and MIA.HuR-KO(−/−).2 groups, where tumor growth was not 
observed (Figs. 4A and B) and reproducible in an independent experiment (Supplementary 
Figs. S3A and B). To then validate these results, we performed the same experiment in Hs 
766T HuR knockout cell line. Nude mice were subcutaneously injected with HsT.HuR-
WT(+/+) and HsT.HuR-KO(−/−) cells showed similar growth results as in MIA PaCa-2 cell 
line (Figs. 4C and D).
Adding HuR in a HuR-null background rescues the tumor growth phenotype
To validate that loss of HuR was responsible for the observed lack of tumor growth, we 
created a stable cell line by overexpressing HuR in MIA.HuR-KO(−/−).1 cells and assaying 
xenograft tumor growth. Results demonstrated that xenografts with MIA.HuR-KO(−/−).1 
cells overexpressing HuR [labeled as (MIA.HuR-KO(−/−)) + HOE] restored the tumor 
formation (1061.4 mm3 vs. 0 mm3; P <0.0002) demonstrating that HuR plays a vital role in 
PDA growth (Fig. 4E and F). These findings using a PDA xenograft model demonstrate that 
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targeted genetic disruption of HuR may prove to be a novel therapeutic strategy to inhibit 
tumor growth as a treatment for PDA.
HuR knockout suppresses xenograft growth in a colon cancer model
In order to determine the effect of HuR knockout on cancer models other than PDA, we 
created HuR knockouts in the colorectal carcinoma HCT116 cell line. Previously, we have 
demonstrated that HuR is upregulated in HCT116 and other CRC cell lines (13,18). A 
similar CRISPR/Cas9-mediated approach was taken, except that a puromycin resistance 
gene/red fluorescent protein (RFP) cassette was inserted into cleavage sites within ELAVL1 
exons 3, 4, or 5 by homology-directed repair (HDR). Clones were screened for puromycin 
resistance and RFP expression and then selected loss of HuR expression (Fig. 5A). 
Confirmation of cassette insertion by PCR-based genotyping identified 2 HuR knockout 
clones (HCT.HuR-KO(−/−).1 and HCT.HuR-KO(−/−).2). Similar to our PDA model, short-
term in vitro growth assays of HCT.HuR-KO(−/−) cells displayed attenuated growth 
compared to the control (Fig. 5B). To determine the effects of HuR loss in colon cancer 
xenografts, we subcutaneously injected nude mice in their hind flanks with equal number of 
HCT.HuR-WT(+/+) and HCT.HuR-KO(−/−) cells. Tumor volumes were measured on alternate 
days and harvested after 35 days. Results showed that tumors in the HCT.HuR-KO(−/−) 
group were dramatically smaller than control HCT.HuR-WT(+/+) (Figs. 5C, D and E), 
consistent to what was observed with PDA cells. Similar results were also observed in 
HCA7 colon cancer cells with CRISPR/Cas9-mediated deletion of HuR (data not shown). 
These results demonstrate that targeted genetic disruption of HuR inhibit cancer growth in 
both PDA and CRC models.
HuR-deficient PDA cells have decreased K-Ras activation
Since disrupted K-Ras signaling is a hallmark of GI cancers and previously deletion of K-ras 
caused a similar dramatic in vivo phenotype (36), we sought to define the role HuR has on 
K-Ras activation. Under normal growth conditions, a loss of HuR results in an increase in K-
Ras and AKT proteins, but interestingly, not a concomitant significance increase in their 
respective activations (Figs. 6A and B). Under acute (16 hr) serum deprivation, MIA.HuR-
WT(+/+) cells respond by increasing K-Ras activation, while HuR knockout cells can no 
longer mount this stress response, and show a significant decline in GTP loading of K-Ras.
Upon extended (72 hr; Figs. 6C and D) serum deprivation, MIA.HuR-KO(−/−).1 cells no 
longer maintained the high levels of compensatory K-Ras expression seen in the acute serum 
starvation, and again K-Ras activation was blunted (unlike HuR competent cells, where K-
Ras-GTP was increased approximately 6 ±2-fold in 72 hr starved versus normal growth 
conditions). While MIA.HuR-KO(−/−).1 cells were capable of augmenting AKT expression 
and activation in normal growth conditions, this survival pathway activation was diminished 
under chronic serum starvation. These data suggest that in PDA, survival mechanisms that 
are in part mitigated by oncogenic, activated KRas can be regulated by HuR function under 
stressed conditions. Thus, proteins responsible for proper KRas activation (i.e. post-
translational modification, trafficking, GEF/GAP activity ratio, etc.) may be targets of HuR 
binding and mRNA stabilization.
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Discussion
CRISPR/Cas9-mediated HuR knockout is a novel way to investigate HuR biology since 
previous studies relied on RNAi-based approaches using shRNA inducible knockdowns or 
siRNA transient transfections (33), where leakiness in the constructs and incomplete 
knockdown can lead to inconsistent results. If amenable, a genomic deletion is an effective 
and unbiased way to evaluate gene function at a more fundamental level. Furthermore, this 
approach allows for identifying off-target effects of molecularly targeted therapies where the 
target is not present in the cell-based model. Using this approach, we deleted HuR in MIA 
PaCa-2, Hs 766T and HCT116 cells, and demonstrated an ablation of HuR protein 
expression compared to wild-type and CRISPR control cells. These commonly used cell 
models of GI cancer will advance the field for studying HuR biology in PDA and CRC, 
along with facilitating current drug discovery where HuR is a target in pre-clinical models 
(14,17,18,21,32,33,35,37–39). However, it should be noted that at the time of acceptance, 
we found that the later passaged MIA.HuR-KO(−/−).1 line seemed to also contain a 
population having an HuR (Wild type) allele (as determined by Sanger sequencing). We 
have re-validated the HuR depletion at early passages where experiments herein where 
performed (data not shown), but we cannot rule out the possibility of a small contamination 
by other single cell clones (e.g., a heterogeneous population emerged of +/+, +/− cells).
It has previously been shown that complete genetic deletion of HuR is embryonically lethal 
in mouse models and this deletion leads to lethality within 10 days (40). Interestingly, mice 
with conditional HuR deletion in a cell/tissue-specific manner are viable as observed in the 
GI tract (41,42), lung epithelium (43,44), brain (45), T-cells (46), and macrophages (47), and 
suggested that deletion of HuR in GI cancer cells would be feasible. Our findings 
demonstrate that PDA and CRC HuR-null cells are able to establish and grow in vitro, 
however, when cells become stressed with chemotoxic agents (Supplementary Fig. S2A), 
growth in soft agar (Fig. 2D and E) and in nude mice they unable to survive (Fig. 4A and B, 
Supplementary Fig. S3A and B, Fig. 4C and D). In principle, the in vivo microenvironment 
simulates a more stressful, hypoxic and glucose deprived environment as compared to an in 
vitro environment containing high nutrient and normoxic conditions.
This work strongly supports the ongoing notion that HuR is a viable target in PDA and CRC. 
Currently, the best-characterized small molecule inhibitor of HuR is the chrysanthone-like 
compound MS-444 that inhibits HuR homodimerization and its cytoplasmic translocation 
(30,48). There have been promising pre-clinical studies that show MS-444 has potent affects 
in CRC mouse models (30) and other studies have demonstrated that MS-444 sensitizes 
PDA cells to oxaliplatin and 5-fluorouracil in relevant tumor microenvironment conditions, 
but issues with stability and bioavailability of MS-444 may hinder first human applications 
(17). Recently, there have been success in identifying other small molecules that disrupt the 
HuR-mRNA interactions, leading to impaired HuR function and premature decay of mRNAs 
that encode proteins related to tumor processes (37). There has also been innovative work 
conjugating siHUR to a 3D nanocarrier in order to target HuR in ovarian tumor–bearing 
mice, resulting in the suppression of tumor growth and ascites development, and ultimately 
prolonging lifespan (37,39). A limitation of the models analyzed herein is the ability to 
assess the specificity of targeting HuR in GI cancer cells. Although previous work has 
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shown that HuR is abundant in GI cancer cells compared to normal adjacent cells, future 
strategies will focus on targeting HuR expression and function specifically in cancer cells. 
Still, these findings indicate that post-transcriptional regulation is a promising target in 
cancer cells and future studies utilizing these cell culture models of PDA and CRC should be 
a valuable resource for advancing the field. It is our hope that HuR inhibitors can eventually 
become a viable therapeutic option for patients either as a monotherapy or in combination of 
other current strategies.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. CRISPR-cas9 system inhibits HuR expression and localization in MIA PaCa-2 PDA 
cells
A, Shown are boxplots of HuR expression levels across 519 samples comprised of normal 
pancreatic tissue (n=46), primary pancreatic adenocarcinomas (n=145), normal colon tissue 
(n=42) and colorectal cancer (n=286). For each boxplot, the black line represents the median 
expression value and the boxes are the 1st and 3rd quartiles. ** p<0.005; *** p<−0.005. B, 
Chromatograms from Sanger sequencing of HuR CRISPR-transfected purified PCR 
products showing the homozygous mutant [MIA.HuR-KO(−/−).1] and homozygous wild type 
[MIA.HuR-KO(+/+)] clones. C, Relative mRNA HuR expression was assessed in different 
clones by qPCR. (Note: only three clones are shown here. Complete list of clones are shown 
in Fig. S1B). D, Relative protein expression of HuR was assessed in different clones by 
immunoblot. (Note: this is a photoshop cropped image of three clones shown in Fig. S1C). 
E, HuR nuclear and cytoplasmic translocation was assessed by immunofluorescence upon 
mitomycin C (MMC), gemcitabine (GEM) and oxaliplatin (Oxa) stressors. MIA.HuR-
WT(+/+) in Figure B–E is a product from MIA PaCa-2 cells with CRISPR control 
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transfection. WT: Wild type; HM: Homozygous mutant. Note: in Fig. B–E, the MIA.HuR-
WT(+/+) clone is ‘MIA.HuR’,
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Figure 2. HuR-deficient cells induce more cell death
A, Cells were stained with Trypan blue and number of dead cells was counted after 24, 48 
and 72 hours for one clone depicting each mutation. Graphs are average of three individual 
experiments. * p<0.003; ** p<0.004. B and C, Cell death was also assessed by cleaved 
caspase 3-activity after 24 hours of cell seeding via FACS. Graphs are average of three 
individual experiments. * p<0.0004. D and E, Long-term cell survival assay was assessed by 
colony formation soft agar assay. Graphs are average of two individual experiments. * 
p<0.003. F, Cell kinetics was measured by pulse chasing the cells by BrdU followed by 
FACS. Graphs are average of two individual experiments.
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Figure 3. HuR-deficient cells failed to bind to its targets
A and B, Ribonucleoprotein immunoprecipitation (RNP-IP) assay was performed to 
determine the binding of HuR to its mRNA targets. Cells were treated with oxaliplatin (1 
μM) for 24 hour and immunoprecipitated either using control IgG or HuR antibodies. 
Western blot showing HuR expression in cytoplasmic and nuclear lysates and 
immunoprecipitated lysates. C, HuR binding to WEE1 and IDH1 mRNA was analyzed by 
qPCR. PARP1 is a non-target of HuR.
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Figure 4. HuR knockout by CRISPR inhibits the PDA xenograft growth
A, Representative images of subcutaneous tumors on the flanks of nude female mice and 
representative pictures of corresponding excised tumors (day 48). B, Tumor growth curves 
of MIA.HuR-WT(+/+), MIA.HuR-KO(+/+), MIA.HuR-KO(−/−).1 and MIA.HuR-KO(−/−).2 
xenografts in nude mice shown in figure A. Data represent means ± SEM of n = 5. ns, non-
significant,* p<0.01; ** p<0.003. C, Representative images of subcutaneous tumors on the 
flanks of nude female mice and their corresponding excised tumors injected with CRISPR 
HuR (HsT.HuR-KO(−/−)) and CRISPR Control (HsT.HuR-WT(+/+)) cells in Hs 766T cell 
line (Day 33). D, Tumor growth curves in HsT.HuR-WT(+/+) and HsT.HuR-KO(−/−) 
xenografts in nude mice shown in figure C. Data represent means ± SEM of n = 4. ns, non-
significant, * p<0.0003. E, Representative images of subcutaneous tumors on the flanks of 
nude female mice and representative pictures of corresponding excised tumors (day 48). F, 
Tumor growth curves of MIA.HuR-WT(+/+), MIA.HuR-KO(−/−).1, and MIA.HuR-KO(−/−).1 
+ HOE xenografts in nude mice shown in figure E. Data represent means ± SEM of n = 5. 
ns, non-significant,* p<0.005; ** p<0.006.
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Figure 5. CRISPR/Cas9 knockout of HuR in colon cancer cells retards cell and tumor growth
A, Western blot analysis of HuR expression in parental HCT116 cells (labeled HCT.HuR-
WT(+/+)) and HuR knockout clones (HCT.HuR-KO(−/−).1 and HCT.HuR-KO(−/−).2). Total 
protein extracts were analyzed by SDS-PAGE and probed for HuR; actin served as a loading 
control. B, In vitro cell growth was measured by MTT assay. Relative absorbance (A570) 
was normalized to cells after 1 day of growth. Cells were used between passages 5 to 12. 
Data is represented as average of 3 independent experiments ± SEM. C, In vivo tumor 
growth of HCT116 cells and HuR knockout clones 1 and 2 (passages 23, 14, and 16, 
respectively) xenografts in nude mice. Tumor volume (mm3) is represented as average of 7 
tumors ± SEM. D and E, Average tumor weight ± SEM and representative tumors excised at 
day 35 are shown. * P <0.05; ** P <0.01; *** P <0.001.
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Figure 6. Loss of HuR diminishes stress-induced K-Ras activation
Immunoblot depiction of total and activated (GTP-bound) K-Ras and AKT protein in MIA 
PaCa-2 cells lacking HuR under 16 (A) or 72 h (C) serum deprivation, respectively. 
Densitometric analysis of immunoblots for acute or (B) or 72 h (D), * p<0.05 HuR(−/−) 
compared to MIA.HuR.WT(+/+), n=3–6 independent experiments. Protein bands are 
normalized to vinculin and are and relative to MIA.HuR.WT(+/+).1 signals.
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